Our Advanced Cancer
Clinical Studies
Our portfolio of blood tests to inform treatment selection and monitor treatment response in patients with advanced cancer is one of the most validated comprehensive liquid biopsy platforms in cancer care. Our Guardant360® test has been cited in more than 200 peer-reviewed publications and 60 clinical outcomes studies to date. We are committed to the highest scientific standards and continue to collaborate with multiple thought leaders around the world to further support the utility of our tests to improve long-term clinical outcomes.
GRECO-Breast Cancer Study
GRECO-Breast Cancer Study
Our GRECO-Breast Cancer study takes a novel, patient-centric approach to enrolling patients with breast cancer who have received the Guardant360 test into this siteless, prospective, observational health outcomes study to create a more comprehensive view of patients’ clinical journey. The primary endpoint of the study is to measure event-free survival stratified by treatment and genomic biomarker.
SIBYL Study
SIBYL Study
The SIBYL (obServation of Therapy Response With lIquid BiopsY evaLualtion) study is designed to evaluate the use of the Guardant360® test to measure response to systemic therapy in patients with unresectable advanced solid tumors in NSCLC, colorectal cancer and breast cancer. The prospective, six-year study aims to enroll 440 patients and will look at clinical data points and treatment outcomes to assess the clinical validity of longitudinal monitoring with circulating tumor DNA (ctDNA) and the correlation of ctDNA dynamics with therapeutic response.
Learn More